

Sheep Anti-Human Factor VII (F.VII) Affinity-Purified IgG (0.5 mg)

Catalogue: SAFVII-AP
Lot No: SAMPLE
Expiry date: **/****
Store at -10 to -20°C.

For Research Use Only.
Not for use in diagnostic procedures.

Description of Factor VII (F.VII)

Factor VII (F.VII, also known as Stable Factor and Proconvertin) is a vitamin K-dependant glycoprotein produced in the liver. Plasma concentration of F.VII is normally around ~0.5 ug/ml (10 nM) in plasma. A deficiency of F.VII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or qualitative (low activity and normal antigen) defect in F.VII function. In its zymogen form F.VII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow F.VII to bind divalent metal ions and participate in calcium-dependant binding interactions. F.VII and activated F.VII (F.VIIa) bind to tissue factor exposed at the site of vascular injury. F.IXa, F.Xa or F.VIIa rapidly activate tissue factor bound F.VII to F.VIIa in the presence of calcium and phospholipid. Thrombin and F.XIIa are able to activate F.VII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen F.VII occurs by proteolysis after residue Arg¹⁵², resulting in a two-chain active serine protease consisting of 30 kDa heavy chain and an 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, F.VIIa is able to activate F.X and F.IX. Free F.VIIa in plasma is remarkably stable, but the activity of F.VIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin¹⁻³.

References and Reviews

1. Rao LVM, Bajaj SP, Rapaport SI: Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-Dependant Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.

3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.

Product Specifications

Description:

Vial containing 0.250 ml of IgG purified by affinity-chromatography on immobilized F.VII. Total protein is 0.5 mg.

Format:

Affinity-purified IgG (APIgG), clear liquid.

Host Animal:

Sheep

Immunogen:

Human Factor VII purified from plasma.

Concentration:

APIgG concentration is 2.00 mg/ml, determined by absorbance using an extinction coefficient ($E_{280}^{1\%}$) of 13.4.

Buffer:

10 mM HEPES, 0.15 M NaCl, 50% (v/v) glycerol, pH 7.4.

Storage:

Store between -10 and -20 °C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use.

Specificity:

This antibody was specific for factor VII as demonstrated by immunoelectrophoresis and ELISA.

Applications:

Suitable as a source of enriched antibodies to human F.VII.

Neutralizing Activity:

Not determined.

Species Cross Reactivity:

Not determined.

Related Products

SAFVII-IG	Sheep anti-Human FVII, IgG from antiserum
SAFVII-HRP	Sheep anti-Human FVII, IgG-peroxidase
FVII-EIA	Paired antibody set for ELISA of FVII, 5 x 96
FVII-DP	Human plasma deficient in FVII, immune depl

Visit our site (www.enzymeresearch.co.uk) for further details.

Enzyme Research Laboratories Ltd

Glamorgan House . Charter Court . Enterprise Park .

Swansea . SA7 9DD . UK

Tel: +44 (0)1792 686070

Email: info@enzymeresearch.co.uk

Website: www.enzymeresearch.co.uk